董事介绍
注:董事持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
James M. Hindman | 男 | Director | 63 | 19.89万美元 | 未持股 | 2023-08-31 |
Robert C. Kill | 男 | Director | 59 | 13.44万美元 | 未持股 | 2023-08-31 |
Beverly A. Huss | 女 | Director | 63 | 19.36万美元 | 未持股 | 2023-08-31 |
Anne B. Le Grand | 女 | Director | 72 | 18.89万美元 | 未持股 | 2023-08-31 |
Suzanne Winter | 女 | President and Chief Executive Officer and Director | 60 | 263.57万美元 | 未持股 | 2023-08-31 |
Byron C. Scott | 男 | Director | 60 | 18.61万美元 | 未持股 | 2023-08-31 |
Mika Nishimura | 女 | Director | 60 | 18.05万美元 | 未持股 | 2023-08-31 |
Robert C. Kill | 男 | Director | 59 | 未披露 | 未持股 | 2023-08-31 |
Joseph E. Whitters | 男 | Chairperson of the Board and Director | 65 | 24.55万美元 | 未持股 | 2023-08-31 |
高管介绍
注:高管持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
Jesse Chew | 男 | Senior Vice President, Chief Legal Officer and Corporate Secretary | 42 | 110.55万美元 | 未持股 | 2023-08-31 |
Suzanne Winter | 女 | President and Chief Executive Officer and Director | 60 | 263.57万美元 | 未持股 | 2023-08-31 |
Ali Pervaiz | 男 | Senior Vice President, Chief Financial Officer | 43 | 108.54万美元 | 未持股 | 2023-08-31 |
Sandeep Chalke | 男 | Senior Vice President, Chief Commercial Officer | 57 | 135.08万美元 | 未持股 | 2023-08-31 |
Michael Hoge | 男 | Senior Vice President, Global Operations | 56 | 102.44万美元 | 未持股 | 2023-08-31 |
Patrick Spine | 男 | Senior Vice President, Chief Administrative Officer | 52 | 108.26万美元 | 未持股 | 2023-08-31 |
董事简历
中英对照 |  中文 |  英文- James M. Hindman
-
James M. Hindman,2014年8月起,担任财务与业务开发执行副总裁、首席财务官。他于1984年加入Allergan,担任过各种财务职位,其中包括高级财务副总裁、财务总监、助理企业财务总监、财务规划与分析副总裁;在2002年2014年8月期间,担任库房、风险与投资者关系高级副总裁。他还是The Allergan Foundation的总裁。加入Allergan之前,他任职于Deloitte, Haskins and Sells。他在Loyola Marymount University获得会计学士学位,在Pepperdine University获得工商管理硕士学位,是一名非执业 的注册会计师。
James M. Hindman,has served as a member of Accuray Incorporated Board since September 2019. Mr. Hindman served in various positions at Allergan, Inc. ("Allergan"), a multi-specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Business Development, and Chief Financial Officer from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company, Urovant Sciences, Inc., a private biopharmaceutical company, and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021, and Sienna Biopharmaceuticals, Inc., a public clinical-stage medical dermatology and aesthetics company, from August 2018 to December 2019. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a privately held biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive). - James M. Hindman,2014年8月起,担任财务与业务开发执行副总裁、首席财务官。他于1984年加入Allergan,担任过各种财务职位,其中包括高级财务副总裁、财务总监、助理企业财务总监、财务规划与分析副总裁;在2002年2014年8月期间,担任库房、风险与投资者关系高级副总裁。他还是The Allergan Foundation的总裁。加入Allergan之前,他任职于Deloitte, Haskins and Sells。他在Loyola Marymount University获得会计学士学位,在Pepperdine University获得工商管理硕士学位,是一名非执业 的注册会计师。
- James M. Hindman,has served as a member of Accuray Incorporated Board since September 2019. Mr. Hindman served in various positions at Allergan, Inc. ("Allergan"), a multi-specialty healthcare company that was acquired by Actavis PLC in 2015, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President, Finance and Business Development, and Chief Financial Officer from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations at Allergan from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of directors of Aatru Medical, LLC, a private medical device company, Urovant Sciences, Inc., a private biopharmaceutical company, and Amolyt Pharma SAS, a private company specializing in developing therapeutic peptides for endocrine and metabolic disease. In the past five years, Mr. Hindman served on the board of directors of Millendo Therapeutics, Inc., a public biotechnology company, from June 2016 to June 2021, and Sienna Biopharmaceuticals, Inc., a public clinical-stage medical dermatology and aesthetics company, from August 2018 to December 2019. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics Holdings, Inc., a privately held biotechnology company, from December 2017 to December 2018. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a certified public accountant in the state of California (inactive).
- Robert C. Kill
-
Robert C. Kill,2015年3月31日以来,一直担任Cogentix的董事、董事长、总裁、首席执行官。2010年12月至2015年3月31日,他担任Uroplasty, Inc. 的董事;2014年5月至2015年3月31日,担任董事长;2013年4月至7月,担任临时首席执行官;2013年7月至2015年3月31日,担任总裁、首席执行官。2012年以来,他一直是私募股权公司Altamont Capital Partners的运营合伙人。2007-2012,他担任Virtual Radiologic Corporation的总裁;2009-2010,担任董事长、首席执行官,当时该公司上市;2010-2012,担任首席执行官、董事,此后该公司私有化,这是全国性的放射学组织,致力于使用技术以提高放射相关操作。加入该公司之前,他担任Misys Healthcare Systems的医师体系总裁,该机构向医师诊所、医师集团、卫生系统、管理式服务组织,提供临床与执业管理软件应用。2002年加入Misys Healthcare Systems之前,他是Entertainment Publications, Inc.的执行副总裁,他于1996-2001年间任职于该公司;也曾担任Baxter Healthcare的运营副总裁,于1986-1996年间,任职于该公司。
Robert C. Kill,has served as a member of Accuray Incorporated Board since January 2023. From 2016 to 2022, Mr. Kill served as a board member of Ascension Ventures, a venture capital fund. From 2017 to 2022, Mr. Kill also served as Chief Executive Officer of Parata Systems, LLC ("Parata Systems"), a pharmacy automation technology provider serving hospital, retail, long term care, mail order and government pharmacies. Prior to joining Parata Systems, Mr. Kill was an operating partner of two private equity funds, Frazier Healthcare Partners from 2016 to 2017 and Altamont Capital Partners from 2012 to 2016. Mr. Kill has also served in varying capacities at Cogentix Medical, Inc. (formerly Uroplasty, Inc.), a publicly traded medical device company that manufactured and marketed neuromodulation and endoscopy technologies, from 2010 to 2016, including most recently as its Chairman & Chief Executive Officer. Mr. Kill's earlier experience includes executive leadership positions with healthcare service and healthcare IT companies. He began his career at Baxter Healthcare and holds a B.A. in Economics from the University of Notre Dame. - Robert C. Kill,2015年3月31日以来,一直担任Cogentix的董事、董事长、总裁、首席执行官。2010年12月至2015年3月31日,他担任Uroplasty, Inc. 的董事;2014年5月至2015年3月31日,担任董事长;2013年4月至7月,担任临时首席执行官;2013年7月至2015年3月31日,担任总裁、首席执行官。2012年以来,他一直是私募股权公司Altamont Capital Partners的运营合伙人。2007-2012,他担任Virtual Radiologic Corporation的总裁;2009-2010,担任董事长、首席执行官,当时该公司上市;2010-2012,担任首席执行官、董事,此后该公司私有化,这是全国性的放射学组织,致力于使用技术以提高放射相关操作。加入该公司之前,他担任Misys Healthcare Systems的医师体系总裁,该机构向医师诊所、医师集团、卫生系统、管理式服务组织,提供临床与执业管理软件应用。2002年加入Misys Healthcare Systems之前,他是Entertainment Publications, Inc.的执行副总裁,他于1996-2001年间任职于该公司;也曾担任Baxter Healthcare的运营副总裁,于1986-1996年间,任职于该公司。
- Robert C. Kill,has served as a member of Accuray Incorporated Board since January 2023. From 2016 to 2022, Mr. Kill served as a board member of Ascension Ventures, a venture capital fund. From 2017 to 2022, Mr. Kill also served as Chief Executive Officer of Parata Systems, LLC ("Parata Systems"), a pharmacy automation technology provider serving hospital, retail, long term care, mail order and government pharmacies. Prior to joining Parata Systems, Mr. Kill was an operating partner of two private equity funds, Frazier Healthcare Partners from 2016 to 2017 and Altamont Capital Partners from 2012 to 2016. Mr. Kill has also served in varying capacities at Cogentix Medical, Inc. (formerly Uroplasty, Inc.), a publicly traded medical device company that manufactured and marketed neuromodulation and endoscopy technologies, from 2010 to 2016, including most recently as its Chairman & Chief Executive Officer. Mr. Kill's earlier experience includes executive leadership positions with healthcare service and healthcare IT companies. He began his career at Baxter Healthcare and holds a B.A. in Economics from the University of Notre Dame.
- Beverly A. Huss
-
BeverlyA.Huss自2018年1月起担任董事会成员。2013年9月起,她担任Qool Therapeutics,Inc.(前身为Thermocure,Inc.)的总裁兼首席执行官,该公司是一家开发阶段公司,专注于为心脏病发作、中风、颅脑创伤和其他医疗状况下的组织保护创造一种新型非侵入性设备。加入Qool之前,Huss从2006年1月到2013年3月担任Vibrynt,Inc.(一家早期医疗设备公司)总裁和首席执行官。此前,她曾担任Guidant Corporation的多种高级领导职务(从1986年到2005年),包括最近担任血管内解决方案总裁,以及血管干预全球营销Vice President。Huss女士的职业生涯始于1982年担任中国中冶工程师。Huss女士目前任职于Qool and Madorra的董事会,该公司是一家私人控股的医疗器械公司,开发改善更年期后生活质量的解决方案。她之前的上市公司董事会经验包括Artes Medical,Wright Medical Group和Dade Behring Holdings,Inc.。Huss女士拥有Pepperdine大学技术管理硕士学位和Illinois大学中国中冶工程学士学位。
Beverly A. Huss,has served as a member of Accuray Incorporated Board since January 2018. From January 2021 to July 2022, Ms. Huss served as the Chief Executive Officer of Pagonia Medical, Inc. ("Pagonia"), a private company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. From September 2013 until December 2020, she served as President and Chief Executive Officer of Qool Therapeutics, Inc. ("Qool"), formerly Thermocure, Inc., a private company focused on temperature management therapies. Prior to joining Qool, Ms. Huss was President and Chief Executive Officer at start-up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, a public company that designs and manufactures cardiovascular products, including, most recently President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Business Unit. Ms. Huss has served on the board of directors of Vicarious Surgical Inc., a medical robotics company, since October 2022; Iridex Corporation, a public medical device company, since March 2022; and Ancora Heart, Inc., a privately-held medical device company developing heart failure treatments, since June 2021. She also serves on the audit committee of Iridex Corporation and Vicarious Surgical Inc. Her prior private company board experience includes Pagonia, Madorra Inc., Coala Life, Inc., Artes Medical, Inc., Wright Medical Group, Inc., and Dade Behring Holdings, Inc. Ms. Huss holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. - BeverlyA.Huss自2018年1月起担任董事会成员。2013年9月起,她担任Qool Therapeutics,Inc.(前身为Thermocure,Inc.)的总裁兼首席执行官,该公司是一家开发阶段公司,专注于为心脏病发作、中风、颅脑创伤和其他医疗状况下的组织保护创造一种新型非侵入性设备。加入Qool之前,Huss从2006年1月到2013年3月担任Vibrynt,Inc.(一家早期医疗设备公司)总裁和首席执行官。此前,她曾担任Guidant Corporation的多种高级领导职务(从1986年到2005年),包括最近担任血管内解决方案总裁,以及血管干预全球营销Vice President。Huss女士的职业生涯始于1982年担任中国中冶工程师。Huss女士目前任职于Qool and Madorra的董事会,该公司是一家私人控股的医疗器械公司,开发改善更年期后生活质量的解决方案。她之前的上市公司董事会经验包括Artes Medical,Wright Medical Group和Dade Behring Holdings,Inc.。Huss女士拥有Pepperdine大学技术管理硕士学位和Illinois大学中国中冶工程学士学位。
- Beverly A. Huss,has served as a member of Accuray Incorporated Board since January 2018. From January 2021 to July 2022, Ms. Huss served as the Chief Executive Officer of Pagonia Medical, Inc. ("Pagonia"), a private company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. From September 2013 until December 2020, she served as President and Chief Executive Officer of Qool Therapeutics, Inc. ("Qool"), formerly Thermocure, Inc., a private company focused on temperature management therapies. Prior to joining Qool, Ms. Huss was President and Chief Executive Officer at start-up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, a public company that designs and manufactures cardiovascular products, including, most recently President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Business Unit. Ms. Huss has served on the board of directors of Vicarious Surgical Inc., a medical robotics company, since October 2022; Iridex Corporation, a public medical device company, since March 2022; and Ancora Heart, Inc., a privately-held medical device company developing heart failure treatments, since June 2021. She also serves on the audit committee of Iridex Corporation and Vicarious Surgical Inc. Her prior private company board experience includes Pagonia, Madorra Inc., Coala Life, Inc., Artes Medical, Inc., Wright Medical Group, Inc., and Dade Behring Holdings, Inc. Ms. Huss holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois.
- Anne B. Le Grand
-
Anne B.Le Grand自2020年7月起担任董事会成员。Le Grand女士自2019年7月起担任IBM Watson Health的Vice President兼成像,生命科学,肿瘤学和基因组学总经理,这是一家机器智能公司,是信息技术公司国际商业机器公司(IBM“;IBM”;)的一个部门。Le Grand女士还于2016年4月至2019年7月担任IBM Watson Health的影像副总裁兼总经理。在IBM Watson Health任职之前,Le Grand女士于2015年1月至2016年4月担任梦百合高级副总裁兼Therapeutics总经理,并于2014年1月至2015年1月担任健康技术公司Philips梦百合业务转型高级副总裁。Le Grand女士此前曾在GE梦百合和Eastman Kodak Company担任多个高级领导职位,并在3M公司医学影像部门开始了她的职业生涯。Le Grand女士拥有夏洛特皇后大学(Queens University of Charlotte)化学学士学位。
Anne B. Le Grand,has served as a member of Accuray Incorporated Board since July 2020. Ms. Le Grand served as a consultant to IBM Watson Health, a machine intelligence company that is a division of IBM, a publicly traded information technology company, from January 2021 to January 2023. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General Manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Business Transformation from January 2014 to January 2015 at Koninkliike Philips N.V., a health technology company. Ms. Le Grand previously served in various senior leadership positions at GE HealthCare Technologies Inc. and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand has served as a member of the board of directors of Medimaps Group, SA, a private medical analytics software company, since May 2022. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte. - Anne B.Le Grand自2020年7月起担任董事会成员。Le Grand女士自2019年7月起担任IBM Watson Health的Vice President兼成像,生命科学,肿瘤学和基因组学总经理,这是一家机器智能公司,是信息技术公司国际商业机器公司(IBM“;IBM”;)的一个部门。Le Grand女士还于2016年4月至2019年7月担任IBM Watson Health的影像副总裁兼总经理。在IBM Watson Health任职之前,Le Grand女士于2015年1月至2016年4月担任梦百合高级副总裁兼Therapeutics总经理,并于2014年1月至2015年1月担任健康技术公司Philips梦百合业务转型高级副总裁。Le Grand女士此前曾在GE梦百合和Eastman Kodak Company担任多个高级领导职位,并在3M公司医学影像部门开始了她的职业生涯。Le Grand女士拥有夏洛特皇后大学(Queens University of Charlotte)化学学士学位。
- Anne B. Le Grand,has served as a member of Accuray Incorporated Board since July 2020. Ms. Le Grand served as a consultant to IBM Watson Health, a machine intelligence company that is a division of IBM, a publicly traded information technology company, from January 2021 to January 2023. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General Manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Business Transformation from January 2014 to January 2015 at Koninkliike Philips N.V., a health technology company. Ms. Le Grand previously served in various senior leadership positions at GE HealthCare Technologies Inc. and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand has served as a member of the board of directors of Medimaps Group, SA, a private medical analytics software company, since May 2022. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte.
- Suzanne Winter
-
Suzanne Winter自2019年10月起担任我们的高级副总裁,首席商务官。在加入公司之前,Winter女士于2015年6月至2019年10月Vice President医疗器械公司Medtronic plc担任美洲地区总经理,并于2011年3月至2015年6月担任通用电气梦百合检测和指导解决方案总经理。在此之前,温特女士曾在多个梦百合行业的全球销售、营销和业务发展领域担任多个高级职位。Winter女士拥有圣劳伦斯大学(Saint Lawrence University)化学学士学位和哈佛大学商学院(Harvard University Graduate School of Business)工商管理硕士学位。
Suzanne Winter,has served as Accuray Incorporated President and Chief Executive Officer since July 2022, as Accuray Incorporated President since July 2021 and as Accuray Incorporated Senior Vice President, Chief Commercial Officer from October 2019 to June 2021. Ms. Winter has also served as a member of Accuray Incorporated Board since April 2022. Prior to joining the Company, Ms. Winter was Vice President, Americas at Medtronic plc, a public medical device company, from June 2015 to October 2019, and General Manager, Detection and Guidance Solutions at General Electric Healthcare, a subsidiary of General Electric Company providing medical technology and pharmaceutical diagnostics, from March 2011 to June 2015. Prior to that, Ms. Winter had served various senior roles in worldwide sales, marketing and business development across a range of healthcare industry segments. Ms. Winter holds a B.S. with a specialization in chemistry from Saint Lawrence University and an M.B.A. from Harvard University Graduate School of Business. - Suzanne Winter自2019年10月起担任我们的高级副总裁,首席商务官。在加入公司之前,Winter女士于2015年6月至2019年10月Vice President医疗器械公司Medtronic plc担任美洲地区总经理,并于2011年3月至2015年6月担任通用电气梦百合检测和指导解决方案总经理。在此之前,温特女士曾在多个梦百合行业的全球销售、营销和业务发展领域担任多个高级职位。Winter女士拥有圣劳伦斯大学(Saint Lawrence University)化学学士学位和哈佛大学商学院(Harvard University Graduate School of Business)工商管理硕士学位。
- Suzanne Winter,has served as Accuray Incorporated President and Chief Executive Officer since July 2022, as Accuray Incorporated President since July 2021 and as Accuray Incorporated Senior Vice President, Chief Commercial Officer from October 2019 to June 2021. Ms. Winter has also served as a member of Accuray Incorporated Board since April 2022. Prior to joining the Company, Ms. Winter was Vice President, Americas at Medtronic plc, a public medical device company, from June 2015 to October 2019, and General Manager, Detection and Guidance Solutions at General Electric Healthcare, a subsidiary of General Electric Company providing medical technology and pharmaceutical diagnostics, from March 2011 to June 2015. Prior to that, Ms. Winter had served various senior roles in worldwide sales, marketing and business development across a range of healthcare industry segments. Ms. Winter holds a B.S. with a specialization in chemistry from Saint Lawrence University and an M.B.A. from Harvard University Graduate School of Business.
- Byron C. Scott
-
Byron C.Scott自2021年2月起担任我们的董事会成员。Scott博士自2016年以来一直担任马萨诸塞州阿默斯特大学艾森伯格管理学院的兼职教师,自2019年12月以来一直担任托马斯·杰斐逊大学杰斐逊人口健康学院的兼职教师,在那里他教授医疗保健质量,患者安全和性能改进。Scott博士于2017年3月至2020年6月担任IBM Watson Health的副首席健康官,在那里他担任顾问,帮助医疗保健组织调整战略并提高绩效,并支持销售,营销和思想领导力。Scott博士曾在Truven Health Analytics任职,该公司于2014年1月至2017年2月被IBM收购,最近于2015年至2017年担任副首席医疗官。从1995年到2013年,他曾任职Emcare公司(医院的医生实践管理公司,是Envision医疗保健的一部分),在那里他担任越来越重要的职务,包括最近担任西部部门的执行副总裁(从2011年到2013年)。Scott博士获得了急诊医学委员会认证,此前从事医学工作超过25年。他目前担任Direct Relief(一个非营利性人道主义组织)的董事会成员,以及the Rady Children’;s Hospital-San Diego的董事会受托人。Scott博士拥有加州大学洛杉矶分校的心理生物学学士学位,加州大学圣地亚哥分校的M.D.和马萨诸塞大学安默斯特分校伊森伯格管理学院的M.B.A.。他是美国企业董事协会认证的董事,并持有卡内基梅隆大学和NACD颁发的CERT网络安全监督证书。
Byron C. Scott,has served as a member of Accuray Incorporated Board since February 2021. Dr. Scott has served as Adjunct Faculty at the University of Massachusetts, Amherst, Isenberg School of Management since 2016, Adjunct Faculty at Jefferson University, College of Population Health since December 2019 where he teaches healthcare quality, patient safety, and performance improvement, and Adjunct, Associate Professor at New York University Stern School of Business since January 2023. Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from March 2017 to June 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership. Dr. Scott served at Truven Health Analytics., an IBM Watson Health company that provides healthcare analytics, from January 2014 to February 2017, most recently as Associate Chief Medical Officer from 2015 to 2017, prior to its acquisition by International Business Machines Corporation ("IBM") in 2016. Dr. Scott previously served at EmCare Holdings Inc., a private hospital-based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the West Division from 2011 to 2013. Dr. Scott is board certified in emergency medicine and previously practiced medicine for over 25 years. He currently serves as a member of the Board of Directors of Providence Health Plan, a privately held health insurance provider, and Direct Relief, a nonprofit humanitarian organization, including Direct Relief Mexico and Direct Relief South Africa. In addition, Dr. Scott also currently serves as Board Trustee, Vice-Chair, Audit and Corporate Responsibility Committee, and member of the Quality, Patient Safety, and Medical Affairs Committee of the Board of Directors at Rady Children's Hospital & Health Center. Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachusetts, Amherst, Isenberg School of Management. He is Directorship Certified by the National Association for Corporate Directors ("NACD") and holds a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD. He is also board certified in healthcare quality management. - Byron C.Scott自2021年2月起担任我们的董事会成员。Scott博士自2016年以来一直担任马萨诸塞州阿默斯特大学艾森伯格管理学院的兼职教师,自2019年12月以来一直担任托马斯·杰斐逊大学杰斐逊人口健康学院的兼职教师,在那里他教授医疗保健质量,患者安全和性能改进。Scott博士于2017年3月至2020年6月担任IBM Watson Health的副首席健康官,在那里他担任顾问,帮助医疗保健组织调整战略并提高绩效,并支持销售,营销和思想领导力。Scott博士曾在Truven Health Analytics任职,该公司于2014年1月至2017年2月被IBM收购,最近于2015年至2017年担任副首席医疗官。从1995年到2013年,他曾任职Emcare公司(医院的医生实践管理公司,是Envision医疗保健的一部分),在那里他担任越来越重要的职务,包括最近担任西部部门的执行副总裁(从2011年到2013年)。Scott博士获得了急诊医学委员会认证,此前从事医学工作超过25年。他目前担任Direct Relief(一个非营利性人道主义组织)的董事会成员,以及the Rady Children’;s Hospital-San Diego的董事会受托人。Scott博士拥有加州大学洛杉矶分校的心理生物学学士学位,加州大学圣地亚哥分校的M.D.和马萨诸塞大学安默斯特分校伊森伯格管理学院的M.B.A.。他是美国企业董事协会认证的董事,并持有卡内基梅隆大学和NACD颁发的CERT网络安全监督证书。
- Byron C. Scott,has served as a member of Accuray Incorporated Board since February 2021. Dr. Scott has served as Adjunct Faculty at the University of Massachusetts, Amherst, Isenberg School of Management since 2016, Adjunct Faculty at Jefferson University, College of Population Health since December 2019 where he teaches healthcare quality, patient safety, and performance improvement, and Adjunct, Associate Professor at New York University Stern School of Business since January 2023. Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from March 2017 to June 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership. Dr. Scott served at Truven Health Analytics., an IBM Watson Health company that provides healthcare analytics, from January 2014 to February 2017, most recently as Associate Chief Medical Officer from 2015 to 2017, prior to its acquisition by International Business Machines Corporation ("IBM") in 2016. Dr. Scott previously served at EmCare Holdings Inc., a private hospital-based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the West Division from 2011 to 2013. Dr. Scott is board certified in emergency medicine and previously practiced medicine for over 25 years. He currently serves as a member of the Board of Directors of Providence Health Plan, a privately held health insurance provider, and Direct Relief, a nonprofit humanitarian organization, including Direct Relief Mexico and Direct Relief South Africa. In addition, Dr. Scott also currently serves as Board Trustee, Vice-Chair, Audit and Corporate Responsibility Committee, and member of the Quality, Patient Safety, and Medical Affairs Committee of the Board of Directors at Rady Children's Hospital & Health Center. Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachusetts, Amherst, Isenberg School of Management. He is Directorship Certified by the National Association for Corporate Directors ("NACD") and holds a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD. He is also board certified in healthcare quality management.
- Mika Nishimura
-
Mika Nishimura自2021年8月起担任我们的董事会成员。自2011年以来,Nishimura女士一直担任Gilde医疗保健Partners(一家专注于生命科学的风险基金)的运营合伙人。她还担任SI-BONE,Inc.的董事会成员,这是一家公共医疗设备公司,致力于解决骨盆解剖的肌肉骨骼疾病。从2015年到2020年,Nishimura女士担任Nvision Medical Corporation的商业化副总裁,这是一家被Boston Scientific收购的早期临床阶段医疗设备公司。此前,她曾担任Auxogyn Incorporated(医疗技术公司,被Progyny,Inc.收购)的商业开发副总裁。职业生涯早期,她曾担任EV3Incorporated公司的副总裁,负责国际销售运营和营销,在那里她曾负责新兴市场的损益。Nishimura女士拥有耶鲁大学经济学学士学位和哈佛大学工商管理研究生院工商管理硕士学位。
Mika Nishimura,has served as a member of Accuray Incorporated Board since August 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn, Inc., a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., a provider for specialists treating a wide range of vascular diseases and disorders, where she held P&L responsibilities for the emerging markets. She has also served as a board member of SI-BONE, Inc., a public medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, since March 2021; a board member of HOYA Corp, a publicly listed Japanese company manufacturing optical products, since June 2022; and as a board advisor to Tristel, plc, a UK public medical technology company, since January 2021. Ms. Nishimura holds an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University. - Mika Nishimura自2021年8月起担任我们的董事会成员。自2011年以来,Nishimura女士一直担任Gilde医疗保健Partners(一家专注于生命科学的风险基金)的运营合伙人。她还担任SI-BONE,Inc.的董事会成员,这是一家公共医疗设备公司,致力于解决骨盆解剖的肌肉骨骼疾病。从2015年到2020年,Nishimura女士担任Nvision Medical Corporation的商业化副总裁,这是一家被Boston Scientific收购的早期临床阶段医疗设备公司。此前,她曾担任Auxogyn Incorporated(医疗技术公司,被Progyny,Inc.收购)的商业开发副总裁。职业生涯早期,她曾担任EV3Incorporated公司的副总裁,负责国际销售运营和营销,在那里她曾负责新兴市场的损益。Nishimura女士拥有耶鲁大学经济学学士学位和哈佛大学工商管理研究生院工商管理硕士学位。
- Mika Nishimura,has served as a member of Accuray Incorporated Board since August 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn, Inc., a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., a provider for specialists treating a wide range of vascular diseases and disorders, where she held P&L responsibilities for the emerging markets. She has also served as a board member of SI-BONE, Inc., a public medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, since March 2021; a board member of HOYA Corp, a publicly listed Japanese company manufacturing optical products, since June 2022; and as a board advisor to Tristel, plc, a UK public medical technology company, since January 2021. Ms. Nishimura holds an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University.
- Robert C. Kill
-
Robert C. Kill,自2023年1月起担任Accuray Incorporated董事会成员。2016年至2022年,基尔担任风险投资基金Ascension Ventures的董事会成员。从2017年到2022年,基尔还担任Parata Systems,LLC(“Parata Systems”)的首席执行官,该公司是一家药房自动化技术提供商,为医院、零售、长期护理、邮购和政府药房提供服务。在加入Parata Systems之前,基尔是两家私募股权基金的运营合伙人,2016年至2017年是Frazier Healthcare Partners,2012年至2016年是Altamont Capital Partners。基尔先生还在2010年至2016年期间担任过Cogentix Medical, Inc.(前身为Uroplasty, Inc.)的不同职务,该公司是一家上市医疗设备公司,生产和销售神经调节和内窥镜技术,最近担任其董事长兼首席执行官。基尔的早期经验包括在医疗保健服务和医疗保健 IT公司担任行政领导职务。他的职业生涯始于Baxter Healthcare,并拥有圣母大学经济学学士学位。
Robert C. Kill,has served as a member of Accuray Incorporated Board since January 2023. From 2016 to 2022, Mr. Kill served as a board member of Ascension Ventures, a venture capital fund. From 2017 to 2022, Mr. Kill also served as Chief Executive Officer of Parata Systems, LLC ("Parata Systems"), a pharmacy automation technology provider serving hospital, retail, long term care, mail order and government pharmacies. Prior to joining Parata Systems, Mr. Kill was an operating partner of two private equity funds, Frazier Healthcare Partners from 2016 to 2017 and Altamont Capital Partners from 2012 to 2016. Mr. Kill has also served in varying capacities at Cogentix Medical, Inc. (formerly Uroplasty, Inc.), a publicly traded medical device company that manufactured and marketed neuromodulation and endoscopy technologies, from 2010 to 2016, including most recently as its Chairman & Chief Executive Officer. Mr. Kill's earlier experience includes executive leadership positions with healthcare service and healthcare IT companies. He began his career at Baxter Healthcare and holds a B.A. in Economics from the University of Notre Dame. - Robert C. Kill,自2023年1月起担任Accuray Incorporated董事会成员。2016年至2022年,基尔担任风险投资基金Ascension Ventures的董事会成员。从2017年到2022年,基尔还担任Parata Systems,LLC(“Parata Systems”)的首席执行官,该公司是一家药房自动化技术提供商,为医院、零售、长期护理、邮购和政府药房提供服务。在加入Parata Systems之前,基尔是两家私募股权基金的运营合伙人,2016年至2017年是Frazier Healthcare Partners,2012年至2016年是Altamont Capital Partners。基尔先生还在2010年至2016年期间担任过Cogentix Medical, Inc.(前身为Uroplasty, Inc.)的不同职务,该公司是一家上市医疗设备公司,生产和销售神经调节和内窥镜技术,最近担任其董事长兼首席执行官。基尔的早期经验包括在医疗保健服务和医疗保健 IT公司担任行政领导职务。他的职业生涯始于Baxter Healthcare,并拥有圣母大学经济学学士学位。
- Robert C. Kill,has served as a member of Accuray Incorporated Board since January 2023. From 2016 to 2022, Mr. Kill served as a board member of Ascension Ventures, a venture capital fund. From 2017 to 2022, Mr. Kill also served as Chief Executive Officer of Parata Systems, LLC ("Parata Systems"), a pharmacy automation technology provider serving hospital, retail, long term care, mail order and government pharmacies. Prior to joining Parata Systems, Mr. Kill was an operating partner of two private equity funds, Frazier Healthcare Partners from 2016 to 2017 and Altamont Capital Partners from 2012 to 2016. Mr. Kill has also served in varying capacities at Cogentix Medical, Inc. (formerly Uroplasty, Inc.), a publicly traded medical device company that manufactured and marketed neuromodulation and endoscopy technologies, from 2010 to 2016, including most recently as its Chairman & Chief Executive Officer. Mr. Kill's earlier experience includes executive leadership positions with healthcare service and healthcare IT companies. He began his career at Baxter Healthcare and holds a B.A. in Economics from the University of Notre Dame.
- Joseph E. Whitters
-
Joseph E. Whitters,自2005年起,一直是Frazier Healthcare(一家私人股本公司)的顾问。从1986年到2005年,他在第一健康集团(First Health Group Corp.)(一家上市的健康管理公司)担任过各种职位,那段期间的大部分时间是担任其首席财务官。1984年到1986年,他还曾担任联合医疗保健集团(United Healthcare Corp)的财务总监。在那之前,他担任Overland Express(一家公开上市的货运公司)的会计和税务经理。他在Peat Marwick,也就是现在的毕马威会计师事务所开始他在公共会计方面的职业生涯。目前,他是InfuSystem控股有限公司(InfuSystem Holdings, Inc.)的董事,这是一家提供流动输液泵和相关临床服务的公司。
Joseph E. Whitters,has served as a member of Accuray Incorporated Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare Partners, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in various capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previously served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Mr. Whitters has served as a member of the board of directors of Spark Networks SE, an operator of premium online dating sites and mobile applications, since July 2021. Mr. Whitters has also served on the boards of directors and audit committees of various public companies, including InfuSystem Holdings, Inc., a provider of infusion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a provider of recovery audit and spend analytics services, from February 2013 to March 2021; Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; and Air Methods Corp., an air medical transportation and air tourism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College. - Joseph E. Whitters,自2005年起,一直是Frazier Healthcare(一家私人股本公司)的顾问。从1986年到2005年,他在第一健康集团(First Health Group Corp.)(一家上市的健康管理公司)担任过各种职位,那段期间的大部分时间是担任其首席财务官。1984年到1986年,他还曾担任联合医疗保健集团(United Healthcare Corp)的财务总监。在那之前,他担任Overland Express(一家公开上市的货运公司)的会计和税务经理。他在Peat Marwick,也就是现在的毕马威会计师事务所开始他在公共会计方面的职业生涯。目前,他是InfuSystem控股有限公司(InfuSystem Holdings, Inc.)的董事,这是一家提供流动输液泵和相关临床服务的公司。
- Joseph E. Whitters,has served as a member of Accuray Incorporated Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare Partners, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in various capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previously served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Mr. Whitters has served as a member of the board of directors of Spark Networks SE, an operator of premium online dating sites and mobile applications, since July 2021. Mr. Whitters has also served on the boards of directors and audit committees of various public companies, including InfuSystem Holdings, Inc., a provider of infusion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a provider of recovery audit and spend analytics services, from February 2013 to March 2021; Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; and Air Methods Corp., an air medical transportation and air tourism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.
高管简历
中英对照 |  中文 |  英文- Jesse Chew
Jesse Chew自2018年10月起担任我们的高级副总裁,总法律顾问兼公司秘书。此前,周先生曾于2018年7月至2018年10月担任我们的Vice President,副总法律顾问以及我们的临时总法律顾问兼公司秘书,2017年7月至2018年7月担任高级公司法律顾问,2014年1月至2017年6月担任公司法律顾问。在加入公司之前,Chew先生是Wilson Sonsini Goodrich and Rosati,P.C.律师事务所的合伙人。Chew先生拥有加州大学戴维斯分校(University of California,Davis)的英语和政治学学士学位以及南加州大学(University of Southern California)的法学博士学位。
Jesse Chew,has served as Accuray Incorporated Senior Vice President, Chief Legal Officer and Corporate Secretary since April 2023 and Accuray Incorporated Senior Vice President, General Counsel and Corporate Secretary from October 2018 to March 2023. Previously, Mr. Chew served as Accuray Incorporated Vice President, Associate General Counsel as well as Accuray Incorporated Interim General Counsel and Corporate Secretary from July 2018 to October 2018, Senior Corporate Counsel from July 2017 to July 2018 and Corporate Counsel from January 2014 to June 2017. Prior to joining the Company, Mr. Chew was an associate at the law firm Wilson Sonsini Goodrich and Rosati, P.C. Mr. Chew holds a B.A. in English and Political Science from the University of California, Davis and a J.D. from the University of Southern California.- Jesse Chew自2018年10月起担任我们的高级副总裁,总法律顾问兼公司秘书。此前,周先生曾于2018年7月至2018年10月担任我们的Vice President,副总法律顾问以及我们的临时总法律顾问兼公司秘书,2017年7月至2018年7月担任高级公司法律顾问,2014年1月至2017年6月担任公司法律顾问。在加入公司之前,Chew先生是Wilson Sonsini Goodrich and Rosati,P.C.律师事务所的合伙人。Chew先生拥有加州大学戴维斯分校(University of California,Davis)的英语和政治学学士学位以及南加州大学(University of Southern California)的法学博士学位。
- Jesse Chew,has served as Accuray Incorporated Senior Vice President, Chief Legal Officer and Corporate Secretary since April 2023 and Accuray Incorporated Senior Vice President, General Counsel and Corporate Secretary from October 2018 to March 2023. Previously, Mr. Chew served as Accuray Incorporated Vice President, Associate General Counsel as well as Accuray Incorporated Interim General Counsel and Corporate Secretary from July 2018 to October 2018, Senior Corporate Counsel from July 2017 to July 2018 and Corporate Counsel from January 2014 to June 2017. Prior to joining the Company, Mr. Chew was an associate at the law firm Wilson Sonsini Goodrich and Rosati, P.C. Mr. Chew holds a B.A. in English and Political Science from the University of California, Davis and a J.D. from the University of Southern California.
- Suzanne Winter
Suzanne Winter自2019年10月起担任我们的高级副总裁,首席商务官。在加入公司之前,Winter女士于2015年6月至2019年10月Vice President医疗器械公司Medtronic plc担任美洲地区总经理,并于2011年3月至2015年6月担任通用电气梦百合检测和指导解决方案总经理。在此之前,温特女士曾在多个梦百合行业的全球销售、营销和业务发展领域担任多个高级职位。Winter女士拥有圣劳伦斯大学(Saint Lawrence University)化学学士学位和哈佛大学商学院(Harvard University Graduate School of Business)工商管理硕士学位。
Suzanne Winter,has served as Accuray Incorporated President and Chief Executive Officer since July 2022, as Accuray Incorporated President since July 2021 and as Accuray Incorporated Senior Vice President, Chief Commercial Officer from October 2019 to June 2021. Ms. Winter has also served as a member of Accuray Incorporated Board since April 2022. Prior to joining the Company, Ms. Winter was Vice President, Americas at Medtronic plc, a public medical device company, from June 2015 to October 2019, and General Manager, Detection and Guidance Solutions at General Electric Healthcare, a subsidiary of General Electric Company providing medical technology and pharmaceutical diagnostics, from March 2011 to June 2015. Prior to that, Ms. Winter had served various senior roles in worldwide sales, marketing and business development across a range of healthcare industry segments. Ms. Winter holds a B.S. with a specialization in chemistry from Saint Lawrence University and an M.B.A. from Harvard University Graduate School of Business.- Suzanne Winter自2019年10月起担任我们的高级副总裁,首席商务官。在加入公司之前,Winter女士于2015年6月至2019年10月Vice President医疗器械公司Medtronic plc担任美洲地区总经理,并于2011年3月至2015年6月担任通用电气梦百合检测和指导解决方案总经理。在此之前,温特女士曾在多个梦百合行业的全球销售、营销和业务发展领域担任多个高级职位。Winter女士拥有圣劳伦斯大学(Saint Lawrence University)化学学士学位和哈佛大学商学院(Harvard University Graduate School of Business)工商管理硕士学位。
- Suzanne Winter,has served as Accuray Incorporated President and Chief Executive Officer since July 2022, as Accuray Incorporated President since July 2021 and as Accuray Incorporated Senior Vice President, Chief Commercial Officer from October 2019 to June 2021. Ms. Winter has also served as a member of Accuray Incorporated Board since April 2022. Prior to joining the Company, Ms. Winter was Vice President, Americas at Medtronic plc, a public medical device company, from June 2015 to October 2019, and General Manager, Detection and Guidance Solutions at General Electric Healthcare, a subsidiary of General Electric Company providing medical technology and pharmaceutical diagnostics, from March 2011 to June 2015. Prior to that, Ms. Winter had served various senior roles in worldwide sales, marketing and business development across a range of healthcare industry segments. Ms. Winter holds a B.S. with a specialization in chemistry from Saint Lawrence University and an M.B.A. from Harvard University Graduate School of Business.
- Ali Pervaiz
Ali Pervaiz,自2022年5月起担任Accuray Incorporated高级副总裁兼首席财务官。此前,Pervaiz先生于2020年8月至2022年5月担任Accuray Incorporated全球商业运营副总裁。在加入本公司之前,Pervaiz先生曾在通用电气公司的子公司、全球医疗技术、药物诊断和数字解决方案创新者GE Healthcare任职超过15年,担任高级财务和运营领导职务,最近的职务是在2018年9月至2020年1月期间担任执行-利润率增长PMO Leader,专注于全球影像业务的利润率扩张,在2017年1月至2018年9月期间担任执行-前进Leader,专注于商业战略和财务转型。在GE Healthcare任职期间,Pervaiz先生曾被选入公司审计人员项目并毕业,他还曾在GE Healthcare担任美国商业诊断成像设备和美国商业生命支持解决方案业务部门的首席财务官。Pervaiz先生拥有芝加哥大学布斯商学院的工商管理硕士学位,专注于金融和运营,威斯康星医学院的医疗保健技术管理硕士学位和马凯特大学的学士学位。
Ali Pervaiz,has served as Accuray Incorporated Senior Vice President, Chief Financial Officer since May 2022. Previously, Mr. Pervaiz served as Accuray Incorporated Vice President, Global Commercial Operations from August 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging business from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previously held business unit Chief Financial Officer roles at GE Healthcare for the US Commercial Diagnostic Imaging Equipment and US Commercial Life Support Solutions businesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Business with focus on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.- Ali Pervaiz,自2022年5月起担任Accuray Incorporated高级副总裁兼首席财务官。此前,Pervaiz先生于2020年8月至2022年5月担任Accuray Incorporated全球商业运营副总裁。在加入本公司之前,Pervaiz先生曾在通用电气公司的子公司、全球医疗技术、药物诊断和数字解决方案创新者GE Healthcare任职超过15年,担任高级财务和运营领导职务,最近的职务是在2018年9月至2020年1月期间担任执行-利润率增长PMO Leader,专注于全球影像业务的利润率扩张,在2017年1月至2018年9月期间担任执行-前进Leader,专注于商业战略和财务转型。在GE Healthcare任职期间,Pervaiz先生曾被选入公司审计人员项目并毕业,他还曾在GE Healthcare担任美国商业诊断成像设备和美国商业生命支持解决方案业务部门的首席财务官。Pervaiz先生拥有芝加哥大学布斯商学院的工商管理硕士学位,专注于金融和运营,威斯康星医学院的医疗保健技术管理硕士学位和马凯特大学的学士学位。
- Ali Pervaiz,has served as Accuray Incorporated Senior Vice President, Chief Financial Officer since May 2022. Previously, Mr. Pervaiz served as Accuray Incorporated Vice President, Global Commercial Operations from August 2020 through May 2022. Prior to joining the Company, Mr. Pervaiz was with GE Healthcare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging business from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previously held business unit Chief Financial Officer roles at GE Healthcare for the US Commercial Diagnostic Imaging Equipment and US Commercial Life Support Solutions businesses. Mr. Pervaiz holds an M.B.A. from the University of Chicago Booth School of Business with focus on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.
- Sandeep Chalke
Sandeep Chalke,自2022年5月起担任Accuray Incorporated高级副总裁兼首席商务官。在加入本公司之前,Chalke先生于2020年4月至2022年5月在全球呼吸护理私营制造商Vyaire Medical,Inc.担任亚太和拉丁美洲地区总裁。在此之前,他于2017年2月至2019年7月担任医疗器械公司美敦力的亚洲太平洋地区糖尿病集团副总裁。2015年5月至2017年1月,查尔克在私营医疗设备公司Acelity L.P担任高级伤口敷料副总裁。查尔克的职业生涯始于通用电气公司,这是一家高科技工业上市公司,曾担任多个领导职位,包括通用电气医疗集团。查尔克先生拥有莱斯特大学的工商管理硕士学位和孟买大学的医疗电子学学位。
Sandeep Chalke,has served as Accuray Incorporated Senior Vice President, Chief Commercial Officer since May 2022. Prior to joining the Company, Mr. Chalke served as President, Asia-Pacific and Latin America regions at Vyaire Medical, Inc., a private global respiratory care manufacturer, from April 2020 to May 2022. Prior to that, he was Vice President of the Diabetes Group in Asian Pactic for Medtronic plc, a medical device company, from February 2017 to July 2019. From May 2015 to January 2017, Mr. Chalke served as Vice President, Advanced Wound Dressing at Acelity L.P, a private medical device company. Mr. Chalke started his career at General Electric Company, a public high tech industrial company, where he served in many leadership positions, including at GE Healthcare. Mr. Chalke holds an M.B.A. from the University of Leicester and a Medical Electronics degree from the University of Mumbai.- Sandeep Chalke,自2022年5月起担任Accuray Incorporated高级副总裁兼首席商务官。在加入本公司之前,Chalke先生于2020年4月至2022年5月在全球呼吸护理私营制造商Vyaire Medical,Inc.担任亚太和拉丁美洲地区总裁。在此之前,他于2017年2月至2019年7月担任医疗器械公司美敦力的亚洲太平洋地区糖尿病集团副总裁。2015年5月至2017年1月,查尔克在私营医疗设备公司Acelity L.P担任高级伤口敷料副总裁。查尔克的职业生涯始于通用电气公司,这是一家高科技工业上市公司,曾担任多个领导职位,包括通用电气医疗集团。查尔克先生拥有莱斯特大学的工商管理硕士学位和孟买大学的医疗电子学学位。
- Sandeep Chalke,has served as Accuray Incorporated Senior Vice President, Chief Commercial Officer since May 2022. Prior to joining the Company, Mr. Chalke served as President, Asia-Pacific and Latin America regions at Vyaire Medical, Inc., a private global respiratory care manufacturer, from April 2020 to May 2022. Prior to that, he was Vice President of the Diabetes Group in Asian Pactic for Medtronic plc, a medical device company, from February 2017 to July 2019. From May 2015 to January 2017, Mr. Chalke served as Vice President, Advanced Wound Dressing at Acelity L.P, a private medical device company. Mr. Chalke started his career at General Electric Company, a public high tech industrial company, where he served in many leadership positions, including at GE Healthcare. Mr. Chalke holds an M.B.A. from the University of Leicester and a Medical Electronics degree from the University of Mumbai.
- Michael Hoge
Michael Hoge,自2020年3月起担任Accuray Incorporated全球运营高级副总裁。此前,从1998年6月到2020年3月,霍格先生在GE Healthcare担任过多个行政领导职务,职责不断增加,最近的职务是GE Healthcare总经理兼全球影像制造业务副总裁。在他职业生涯的早期,霍格先生曾在Generac Power Systems,Inc.和卡特彼勒有限公司担任过各种工程职务。霍格先生拥有威斯康星大学麦迪逊分校机械工程学士学位和马凯特大学工商管理硕士学位。
Michael Hoge,has served as Accuray Incorporated Senior Vice President, Global Operations since March 2020. Previously, from June 1998 to March 2020, Mr. Hoge served in various executive leadership roles of increasing responsibility with GE Healthcare, most recently as its General Manager, Vice President of Manufacturing Operations, Global Imaging. Earlier in his career, Mr. Hoge worked in various engineering roles at Generac Power Systems, Inc. and Caterpillar Inc. Mr. Hoge holds a Bachelor's Degree in Mechanical Engineering from University of Wisconsin, Madison and an M.B.A. from Marquette University.- Michael Hoge,自2020年3月起担任Accuray Incorporated全球运营高级副总裁。此前,从1998年6月到2020年3月,霍格先生在GE Healthcare担任过多个行政领导职务,职责不断增加,最近的职务是GE Healthcare总经理兼全球影像制造业务副总裁。在他职业生涯的早期,霍格先生曾在Generac Power Systems,Inc.和卡特彼勒有限公司担任过各种工程职务。霍格先生拥有威斯康星大学麦迪逊分校机械工程学士学位和马凯特大学工商管理硕士学位。
- Michael Hoge,has served as Accuray Incorporated Senior Vice President, Global Operations since March 2020. Previously, from June 1998 to March 2020, Mr. Hoge served in various executive leadership roles of increasing responsibility with GE Healthcare, most recently as its General Manager, Vice President of Manufacturing Operations, Global Imaging. Earlier in his career, Mr. Hoge worked in various engineering roles at Generac Power Systems, Inc. and Caterpillar Inc. Mr. Hoge holds a Bachelor's Degree in Mechanical Engineering from University of Wisconsin, Madison and an M.B.A. from Marquette University.
- Patrick Spine
Patrick Spine自2018年10月起担任高级副总裁,首席行政官。此前,Spine先生于2018年4月至2018年10月担任我们的高级副总裁,人力资源。在加入该公司之前,斯皮恩曾担任多个人力资源领导职位,包括2012年5月至2018年4月在全球合同研究机构PRA Health Sciences担任人力资源Vice President,以及在专业制药和药物输送公司好比拉医疗保健公司担任人力资源总监,从2010年8月到2012年5月。在此之前,Spine从2005年6月到2010年7月在Eaton(一家电力管理公司)担任多个人力资源领导职位。Spine先生拥有Robert Morris University的工商管理学士学位,主修人力资源,以及LaRoche College的人力资源管理硕士学位。
Patrick Spine,has served as Accuray Incorporated Senior Vice President, Chief Administrative Officer since October 2018. Previously, Mr. Spine served as Accuray Incorporated Senior Vice President, Human Resources from April 2018 to October 2018. Prior to joining the Company, Mr. Spine held multiple human resources leadership positions, including Vice President of Human Resources at PRA Health Sciences, Inc., a global contract research organization, from May 2012 to April 2018 and Director of Human Resources at HOSPIRA, Inc., a specialty pharmaceutical and medication delivery company, from August 2010 to May 2012. Prior to that, Mr. Spine held various HR-leadership positions at Eaton Corporation plc, a power management company, from June 2005 to July 2010. Mr. Spine holds a B.S. in Business Administration, major in Human Resources, from Robert Morris University and a M.S. in Human Resources Management from LaRoche College.- Patrick Spine自2018年10月起担任高级副总裁,首席行政官。此前,Spine先生于2018年4月至2018年10月担任我们的高级副总裁,人力资源。在加入该公司之前,斯皮恩曾担任多个人力资源领导职位,包括2012年5月至2018年4月在全球合同研究机构PRA Health Sciences担任人力资源Vice President,以及在专业制药和药物输送公司好比拉医疗保健公司担任人力资源总监,从2010年8月到2012年5月。在此之前,Spine从2005年6月到2010年7月在Eaton(一家电力管理公司)担任多个人力资源领导职位。Spine先生拥有Robert Morris University的工商管理学士学位,主修人力资源,以及LaRoche College的人力资源管理硕士学位。
- Patrick Spine,has served as Accuray Incorporated Senior Vice President, Chief Administrative Officer since October 2018. Previously, Mr. Spine served as Accuray Incorporated Senior Vice President, Human Resources from April 2018 to October 2018. Prior to joining the Company, Mr. Spine held multiple human resources leadership positions, including Vice President of Human Resources at PRA Health Sciences, Inc., a global contract research organization, from May 2012 to April 2018 and Director of Human Resources at HOSPIRA, Inc., a specialty pharmaceutical and medication delivery company, from August 2010 to May 2012. Prior to that, Mr. Spine held various HR-leadership positions at Eaton Corporation plc, a power management company, from June 2005 to July 2010. Mr. Spine holds a B.S. in Business Administration, major in Human Resources, from Robert Morris University and a M.S. in Human Resources Management from LaRoche College.